Drugs / WALVAX PCV13
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05092386 Comparator | Jan 2023 → May 2024 | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WALVAX PCV13 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05092386 ↗ |
| Modality | Vaccine | “The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd.” NCT05092386 ↗ |